Baseline patient demographics
| Characteristics* . | ITT cohort (n = 64) . |
|---|---|
| Median age (range), y | 75 (61-89) |
| Male, n (%) | 34 (53) |
| White, n (%) | 58 (91) |
| ECOG PS, n (%) | |
| 0 | 27 (42) |
| 1 | 23 (36) |
| 2 | 14 (22) |
| Primary diagnosis | |
| De novo AML, n (%) | 36 (56) |
| Secondary AML, n (%) | 28 (44) |
| Median marrow blasts (range) | 38.5 (5-92) |
| Cytogenetics, n (%)† | |
| Adverse | 18 (28) |
| Intermediate | 32 (50) |
| Favorable | 2 (3) |
| Unclassified | 9 (14) |
| Not available | 3 (5) |
| Characteristics* . | ITT cohort (n = 64) . |
|---|---|
| Median age (range), y | 75 (61-89) |
| Male, n (%) | 34 (53) |
| White, n (%) | 58 (91) |
| ECOG PS, n (%) | |
| 0 | 27 (42) |
| 1 | 23 (36) |
| 2 | 14 (22) |
| Primary diagnosis | |
| De novo AML, n (%) | 36 (56) |
| Secondary AML, n (%) | 28 (44) |
| Median marrow blasts (range) | 38.5 (5-92) |
| Cytogenetics, n (%)† | |
| Adverse | 18 (28) |
| Intermediate | 32 (50) |
| Favorable | 2 (3) |
| Unclassified | 9 (14) |
| Not available | 3 (5) |